This increased c-Met signaling network in prostate cancer cells could be considered as one of the reasons why targeting c-Met and VEGFR2 kinases with a small molecule, cabozantinib (XL-184), resolved bone and soft tissue metastases in a broad spectrum of solid tumors in patients [20], [21]. The gene discussed is MET; the disease is prostate carcinoma.